Baird raised the firm’s price target on Regeneron to $800 from $756 and keeps a Neutral rating on the shares. The analyst raised his target on impressive Dupixent results in COPD and also raised his sales estimates upward based on the data.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on REGN: